LIUDAZHI, Distinguished Chair Professor at the Institute of Cell and Gene Technology, Shenzhen University of Advanced Technology; former Professor at the University of California, Davis. He was the first internationally to propose the original academic concept “Aberrant Cell Cycle Diseases (ACCD)”, systematically revealing the common pathological basis of nervous system diseases and cancer—aberrant cell cycle. Based on the ACCD theoretical framework, the Liu research group established an interdisciplinary research project titled “Mechanism Research and Industrial Translation of Anti-Cancer Elements (Anti-Cancer miRNA Enhancers, Oncogene/Kinase Inhibitors) in Treating Nervous System Diseases”, covering research areas including: Major nervous system diseases such as traumatic brain injury, cerebral thrombosis, cerebral hemorrhage, and Alzheimer’s disease, maintaining original leadership in this international frontier field. A series of research and teaching achievements include: Two NIH R01 grants, three patent applications, over 70 professional papers published, authoring a new course “The Cell Cycle and Disease”, and supervising more than 10 medical doctoral students and postdoctoral fellows.

Mechanism Research and Industrial Translation of Anti-Cancer Elements (Anti-Cancer microRNA Enhancers, Oncogene/Kinase Inhibitors) in Treating Acute Brain Injury and Other Nervous System Diseases

1994-1998, Bachelor’s Degree, Anhui University of Chinese Medicine

1999-2002, Master’s Degree, Tongji Medical College of Huazhong University of Science and Technology

2002-2005, PhD, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2005-2006, Assistant Researcher, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2006-2010, Postdoctoral Fellow, University of California, Davis

2010-2016, Assistant Research Professor, University of California, Davis

2016-2020, Associate Professor, University of California, Davis

2020-2025, Professor, University of California, Davis

2025–present, Distinguished Chair Professor, Shenzhen University of Advanced Technology

Projects Led

2015-2020, NIH R01, Principal Investigator, Kinase Src Inhibitors for Brain Injury Treatment

2020-2025, NIH R01, Principal Investigator, Anti-Cancer microRNAs for Brain Injury Treatment

1.Liu DZ（First and Corresponding Author）,Ander BP, Cell Cycle Inhibition without Disruption of Neurogenesis is a Strategy for Treatment of Aberrant Cell Cycle Diseases: an Update.ScientificWorldJournal. 2012; 2012:491737.PMID: 22547985

2.Lui A, Do T, Alzayat O, Yu N, Phyu S, Santuya HJ, Liang B, Kailash V, Liu D, Inslicht SS, Shahlaie K,Liu DZ（Seniorand Corresponding Author）. Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders.Pharmaceuticals,2024 Mar 27;17(4):426.PMID:38675388

3.Lui A, Vanleuven J, Perekopskiy D, Liu D, Xu D, Alzayat O, Elgokhy T, Do T, Gann M, Martin R,Liu DZ（Seniorand Corresponding Author）. FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials forNeurological Disorders. Pharmaceuticals, 2022 Dec 13;15(12):1546.PMID:36558997

4.Liu DZ（Sole Inventor）.Methods (of MicroRNA Therapy) for Treating Brain Injury. (Patent)https://patents.google.com/patent/WO2019165267A1/en

5.LiuDZ（First Inventor）,Lyeth B.Martin R, Shahlaie K.Methods (of Using Dasatinib)for Treating Brain Injury. (Patent)

https://patents.google.com/patent/WO2023097071A2/en

6.LiuDZ（First Inventor）,Lyeth B.Martin R, Shahlaie K.Methods (of Using Abemaciclib)for Treating Brain Injury. (Patent)

https://patents.google.com/patent/WO2023107428A1/en